-
1Academic Journal
Authors: Е. V. Ryabchenko, Е. В. Рябченко
Source: Malignant tumours; Том 13, № 4 (2023); 18-27 ; Злокачественные опухоли; Том 13, № 4 (2023); 18-27 ; 2587-6813 ; 2224-5057
Subject Terms: метастаз, multifocal papillary cancer, papillary carcinoma, central lymphadenectomy, metastasis, мультифокальный папиллярный рак, папиллярная карцинома, центральная лимфаденэктомия
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/1274/912; Cooper DS, Doherty GM, et al. American Thyroid Association Guidelines Taskforce on Thyroid N Differentiated Thyroid C. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167–1214.; Kwak JY, Kim EK, Kim JK, et al. Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area. Head Neck 2010; 32:490–498.; Ahmed R, Al-Shaikh S, Akhtar M. Hashimoto thyroiditis: a century later. Adv Anat Pathol 2012; 19:181–186.; Jankovic B, Le KT, Hershman JM. Clinical review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metabol 2013; 98:474–482.; Fugazzola L, Colombo C, Perrino M, et al. Papillary thyroid carcinoma and inflammation. Frontiers Endocrinol 2011; 2:88.; Lee JH, Kim Y, Choi JW, et al. The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Eur J Endocrinol 2013; 168:343–349.; Kim EY, Kim WG, Kim WB, et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol 2009; 71:581–586.]; Liu Y, Lv HJ, Zhang SQ, Shi BY, Sun YS. The Impact of Coexistent Hashimoto’s Thyroiditis on Central Compartment Lymph Node Metastasis in Papillary Thyroid Carcinoma. Front Endocrinol (2021) 12:772071:772071. doi:10.3389/fendo. 2021.772071; Schindler AM, van Melle G, Evequoz B, et al. Prognostic factors in papillary carcinoma of the thyroid. Cancer 1991; 68:324–330.; Anil C, Goksel S, Gursoy A. Hashimoto’s thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid 2010; 20:601–606.; Bircan HY, Koc B, Akarsu C, et al. Is Hashimoto’s thyroiditis a prognostic factor for thyroid papillary microcarcinoma? Eur Rev Med Pharmacol Sci 2014; 18:1910–1915.; Cipolla C, Sandonato L, Graceffa G, et al. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg 2005; 71:874–878.]; Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 2015; 47:127–141.; Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 1955; 70:291–297.; Jayaprakash K, Kishanprasad H, Hegde P, et al. Hashimotos thyroiditis with coexistent papillary carcinoma and non-Hodgkin lymphoma-thyroid. Ann Med Health Sci Res 2014; 4:268–270.; Mazeh H, Samet Y, Hochstein D, et al. Multifocality in well-differentiated thyroid carcinomas calls for total thyroidectomy. Am J Surg 2011; 201:770–775.; Zhang Y, Dai J, Wu T, et al. The study of the coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma. J Cancer Res Clin Oncol 2014; 140:1021–1026.; Ito Y, Miyauchi A. Nonoperative management of low-risk differentiated thyroid carcinoma. Curr Opin Oncol 2015; 27:15–20.; Podnos YD, Smith D, Wagman LD, et al. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 2005; 71:731–734.; Yu XM, Wan Y, Sippel RS, et al. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 2011; 254:653–660.; Vrachimis A, Gerss J, Stoyke M, et al. No significant difference in the prognostic value of the 5th and 7th editions of AJCC staging for differentiated thyroid cancer. Clin Endocrinol 2014; 80:911–917.; Kim KJ, Kim SM, Lee YS, et al. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2,309 consecutive patients. Ann Surg Oncol 2015; 22:125–131.; Hyun SM, Song HY, Kim SY, et al. Impact of combined prophylactic unilateral central neck dissection and hemithyroidectomy in patients with papillary thyroid microcarcinoma. Ann Surg Oncol 2012; 19:591–596.; Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012; 22:1144–1152.; Kurukahvecioglu O, Taneri F, Yuksel O, et al. Total thyroidectomy for the treatment of Hashimoto’s thyroiditis coexisting with papillary thyroid carcinoma. Adv Ther 2007; 24:510–516.; Repplinger D, Bargren A, Zhang YW, et al. Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 2008; 150:49–52.; Jin S, Sugitani I. Narrative Review of Management of Thyroid Surgery Complications. Gland Surg (2021) 10 (3):1135–46. doi:10.21037/gs-20-859; Consorti F, Loponte M, Milazzo F, et al. Risk of malignancy from thyroid nodular disease as an element of clinical management of patients with Hashimoto’s thyroiditis. Eur Surg Res 2010; 45:333–337.; Kebebew E, Treseler PA, Ituarte PH, et al. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg 2001; 25:632–637.; Kim HS, Choi YJ, Yun JS. Features of papillary thyroid microcarcinoma in the presence and absence of lymphocytic thyroiditis. Endocr Pathol 2010; 21:149–153.; Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28:742–762.; Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007; 148:936–941.]; Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 115:1068–1081.; Bozec A, Lassalle S, Hofman V, et al. The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem 2010; 17:3449–3461.; Zeng RC, Jin LP, Chen ED, et al. Potential relationship between Hashimoto’s thyroiditis and BRAF mutation status in papillary thyroid cancer. Head Neck 2015.; Jin L, Sebo TJ, Nakamura N, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 2006; 15:136–143.; Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246:466–470.; Jiang LH, Yin KX, Wen QL, Chen C, Tan Z. Predictive Risk-Scoring Model for Central Lymph Node Metastasis and Predictors of Recurrence in Papillary Thyroid Carcinoma. Sci Rep (2020) 10 (1):710. doi:10.1038/s41598-019-55991-1; Oler G, Camacho CP, Hojaij FC, et al. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res 2008; 14:4735–4742.; Ehlers M, Schott M. Hashimoto’s thyroiditis and papillary thyroid cancer: are they immunologically linked? Trends Endocrinol Metabol 2014; 25:656–664.; Cunha LL, Morari EC, Guihen AC, et al. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol 2012; 77:918–925.; https://www.malignanttumors.org/jour/article/view/1274
-
2Academic Journal
Authors: E. V. Ryabchenko, Е. В. Рябченко
Source: Siberian journal of oncology; Том 21, № 3 (2022); 168-173 ; Сибирский онкологический журнал; Том 21, № 3 (2022); 168-173 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2022-21-3
Subject Terms: центральная лимфаденэктомия, calcitonin, procalcitonin, COVID-19, thyroidectomy, central lymphadenectomy, кальцитонин, прокальцитонин, тиреоидэктомия
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/2175/1000; Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., Chen H.D., Chen J., Luo Y., Guo H., Jiang R.D., Liu M.Q., Chen Y., Shen X.R., Wang X., Zheng X.S., Zhao K., Chen Q.J., Deng F., Liu L.L., Yan B., Zhan F.X., Wang Y.Y., Xiao G.F., Shi Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270–3. doi:10.1038/s41586-020-2012-7.; Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5(4): 536–44. doi:10.1038/s41564-020-0695-z.; Ahmed S., Jafri L., Hoodbhoy Z., Siddiqui I. Prognostic Value of Serum Procalcitonin in COVID-19 Patients: A Systematic Review. Indian J Crit Care Med. 2021; 25(1): 77–84. doi:10.5005/jp-journals-10071-23706.; Xu J.B., Xu C., Zhang R.B., Wu M., Pan C.K., Li X.J., Wang Q., Zeng F.F., Zhu S. Associations of procalcitonin, C-reaction protein and neutrophil-to-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China. Sci Rep. 2020; 10(1): 15058. doi:10.1038/s41598- 020-72164-7.; Algeciras-Schimnich A., Preissner C.M., Theobald J.P., Finseth M.S., Grebe S.K. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2009; 94(3): 861–8. doi:10.1210/jc.2008-1862.; Karagiannis A.K., Girio-Fragkoulakis C., Nakouti T. Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review. Anticancer Res. 2016; 36(8): 3803–10.; Pacini F., Castagna M.G., Cipri C., Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010; 22(6): 475–85. doi:10.1016/j.clon.2010.05.002.; Meijer J.A., le Cessie S., van den Hout W.B., Kievit J., Schoones J.W., Romijn J.A., Smit J.W. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol (Oxf). 2010; 72(4): 534–42. doi:10.1111/j.1365-2265.2009.03666.x.; Cabanillas M.E., Hu M.I., Jimenez C., Grubbs E.G., Cote G.J. Treating medullary thyroid cancer in the age of targeted therapy. Int J Endocr Oncol. 2014; 1(2): 203–16. doi:10.2217/ije.14.26.; Gianotti L., D'Agnano S., Pettiti G., Tassone F., Giraudo G., Lauro C., Lauria G., Del Bono V., Borretta G. Persistence of Elevated Procalcitonin in a Patient with Coronavirus Disease 2019 Uncovered a Diagnosis of Medullary Thyroid Carcinoma. AACE Clin Case Rep. 2021; 7(5): 288–92. doi:10.1016/j.aace.2021.05.001.; Lam S.D., Bordin N., Waman V.P., Scholes H.M., Ashford P., Sen N., van Dorp L., Rauer C., Dawson N.L., Pang C.S.M., Abbasian M., Sillitoe I., Edwards S.J.L., Fraternali F., Lees J.G., Santini J.M., Orengo C.A. SARS-CoV-2 spike protein predicted to form complexes with host receptor protein orthologues from a broad range of mammals. Sci Rep. 2020; 10(1): 16471. doi:10.1038/s41598-020-71936-5.; Han T., Kang J., Li G., Ge J., Gu J. Analysis of 2019-nCoV receptor ACE2 expression in diferent tissues and its signifcance study. Ann Transl Med. 2020; 8(17): 1077. doi:10.21037/atm-20-4281.; Lazartigues E., Qadir M.M.F., Mauvais-Jarvis F. Endocrine Signifcance of SARS-CoV-2’s Reliance on ACE2. Endocrinology. 2020; 161(9). doi:10.1210/endocr/bqaa108.; Rotondi M., Coperchini F., Ricci G., Denegri M., Croce L., Ngnitejeu S.T., Villani L., Magri F., Latrofa F., Chiovato L. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID19-related subacute thyroiditis. J Endocrinol Invest. 2021; 44(5): 1085–90. doi:10.1007/s40618-020-01436-w.; Sigrist C.J., Bridge A., Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral Res. 2020; 177. doi:10.1016/j. antiviral.2020.104759.; Davis P.J., Mousa S.A., Lin H.Y. Nongenomic Actions of Thyroid Hormone: The Integrin Component. Physiol Rev. 2021; 101(1): 319–52. doi:10.1152/physrev.00038.2019.; Schmohl K.A., Mueller A.M., Dohmann M., Spellerberg R., Urnauer S., Schwenk N., Ziegler S.I., Bartenstein P., Nelson P.J., Spitzweg C. Integrin αvβ3-Mediated Efects of Thyroid Hormones on Mesenchymal Stem Cells in Tumor Angiogenesis. Thyroid. 2019; 29(12): 1843–57. doi:10.1089/thy.2019.0413.; Davis P.J., Lin H.Y., Hercbergs A., Mousa S.A. Actions of L-thyroxine (T4) and Tetraiodothyroacetic Acid (Tetrac) on Gene Expression in Thyroid Cancer Cells. Genes (Basel). 2020; 11(7): 755. doi:10.3390/genes11070755.; Davis P.J., Lin H.Y., Hercbergs A., Keating K.A., Mousa S.A. Coronaviruses and Integrin αvβ3: Does Thyroid Hormone Modify the Relationship? Endocr Res. 2020; 45(3): 210–5. doi:10.1080/07435800.2020.1767127.; https://www.siboncoj.ru/jour/article/view/2175
-
3Academic Journal
Authors: A. F. Romanchishen, F. A. Romanchishen, K. V. Vabalaite, А. Ф. Романчишен, Ф. А. Романчишен, К. В. Вабалайте
Source: Head and Neck Tumors (HNT); № 2 (2013); 21-24 ; Опухоли головы и шеи; № 2 (2013); 21-24 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2013-0-2
File Description: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/5/7; Gharib H., Papini E., Valcavi R. et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006;12(1):63–102.; Popadich A., Levin O., Lee J.C. et al. A multicenter chort study of total thyroidectomy and routine central lymph node dissection for cNO papillary thyroid cancer. Surgery 2011;150(6):1048–57.; Ballantyne A.J. Neck dissection for thyroid cancer. Semin Surg Oncol 1991;7(2):100–6.; Block M.A. Primary treatment of welldifferentiated thyroid cancer. J Surg Oncol 1981;16(3):279–88.; Lacour J., L'Heritier M., Petit J.Y. et al. Surgical treatment of differentiated thyroid cancer at the Institute Gustave-Roussy. Ann Radiol 1977;20(8):767–70.; Machens A., Hinze R., Tomusch O., Dralle H. Pattern of nodal metastases for primary and reoperative thyroid cancer. World J Surg 2002;26:22–8.; Mayer M., Colon J., Bobin J.Y., Blondet R. Indications and limits of surgery in thyroid carcinoma. Ann Radiol 1977;20(8):771–3.; Reynier J., Vallee G., Brun J.G. et al. Cancers thyroidiens: Indications et resultats therapeutiques. Nouv Press Med 1979;8(3):189–93.; Di Matteo G. La limfadenectomia per cancro tiroideo. Quando, come, perche. Minerva Chir 1980;35(23–24):1923–6.; Travagli J.P., Schlumberger M., Parmentier C. et al. Lymph node surgery in patients with differentiated thyroid carcinoma. In: Thyroid cancer (Eds. C. Jaffiol, G. Milhaud). Amsterdam, 1985. Pp. 161–165.; Tubiana M., Schlumberger M., Rougier P. et al. Long-term results and prognostics factors in patients with differentiated thyroid carcinoma. Cancer 1985;55(4):794–804.; Камардин Л.Н., Романчишен А.Ф. Решенные и спорные вопросы в диагностике и лечении рака щитовидной железы. Вестник хирургии 1983;1:15–20.; Giammanco M., Cimino G. Lymphadenectomy in well differentiated thyroid carcinoma. Minerva Chir 2001;56(1):77–84.; Романчишен А. Ф., Липская Е.В., Колосюк В.А. Хирургическая тактика диагностики и лечения больных с дифференцированным раком щитовидной железы. Вестник хирургии 2004;163(1):11–5.; Шевченко С.П., Белобородов В.А., Сидоров С.В. и др. Диссекция центральной клетчатки шеи при высокодифференцированном раке щитовидной железы. Материалы Первого украинско-российского симпозиума по эндокринной хирургии с международным участием «Современные аспекты хирургического лечения эндокринной патологии». Киев, 13–14 октября 2006 г. С. 18–19.; Чернышев В.А., Хамидуллин Р.Г., Зинченко С.В., Рудык А.Н. Центральная лимфодиссекция при раке щитовидной железы. Материалы межрегиональной конференции с международным участием «Рак щитовидной железы и эндемический зоб». Екатеринбург, 05–07 апреля 2007 г. C. 49–50.; Shah J.P. Surgical management of cervical lymph nodes. Материалы межрегиональной конференции с международным участием «Рак щитовидной железы и эндемический зоб». Екатеринбург, 05–07 апреля 2007 г. C. 29–30.; Лежнев Н.Ф. Зоб в России. М.: Тип. Борисенко, 1904. 341 с. 19. Lahey F.H. Routine dissection and demonstration recurrent laryngeal nerve in subtotal thyroidectomy. Surg Gynecol Obstet 1938;66:774–7.; https://ogsh.abvpress.ru/jour/article/view/5
-
4Academic Journal
Authors: Рябченко, Е.
Subject Terms: РАК ЩИТОВИДНОЙ ЖЕЛЕЗЫ, АУТОИММУННЫЙ ТИРЕОДИТ, ТИРЕОИДЭКТОМИЯ, ЦЕНТРАЛЬНАЯ ЛИМФАДЕНЭКТОМИЯ
File Description: text/html
-
5Academic Journal
-
6Academic Journal
Authors: Румянцев, П., Ильин, А., Румянцева, У.
Subject Terms: МЕДУЛЛЯРНЫЙ РАК ЩИТОВИДНОЙ ЖЕЛЕЗЫ, ТИРЕОИДЭКТОМИЯ, ЦЕНТРАЛЬНАЯ ЛИМФАДЕНЭКТОМИЯ
File Description: text/html
-
7Academic Journal
Source: Опухоли головы и шеи.
File Description: text/html
-
8Academic Journal
Source: Новости хирургии.
Subject Terms: РАК ЩИТОВИДНОЙ ЖЕЛЕЗЫ, АУТОИММУННЫЙ ТИРЕОДИТ, ТИРЕОИДЭКТОМИЯ, ЦЕНТРАЛЬНАЯ ЛИМФАДЕНЭКТОМИЯ, 3. Good health
File Description: text/html
-
9Academic Journal
Source: Эндокринная хирургия.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, МЕДУЛЛЯРНЫЙ РАК ЩИТОВИДНОЙ ЖЕЛЕЗЫ, ТИРЕОИДЭКТОМИЯ, ЦЕНТРАЛЬНАЯ ЛИМФАДЕНЭКТОМИЯ, 3. Good health
File Description: text/html
